| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2013-12-543736 |
| P698 | PubMed publication ID | 24711661 |
| P50 | author | Kristina Maas-Bauer | Q87635677 |
| P2093 | author name string | Christian Peschel | |
| Jürgen Finke | |||
| Sophia Chen | |||
| Annette Schmitt-Graeff | |||
| Justus Duyster | |||
| Nikolas von Bubnoff | |||
| Silvia Spoerl | |||
| Martina Schmickl | |||
| Hendrik Poeck | |||
| Robert Zeiser | |||
| Vera Otten | |||
| Mareike Verbeek | |||
| Michael Bscheider | |||
| Nimitha R Mathew | |||
| Julius Fischer | |||
| Tony Mueller | |||
| P433 | issue | 24 | |
| P304 | page(s) | 3832-3842 | |
| P577 | publication date | 2014-04-07 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | |
| P478 | volume | 123 |
| Q39378276 | A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. |
| Q47917118 | A20 deletion in T cells modulates acute graft-versus-host disease in mice |
| Q34209366 | Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD |
| Q64056508 | Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease |
| Q49679320 | Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy |
| Q54937398 | Advance in Targeted Immunotherapy for Graft-Versus-Host Disease. |
| Q35586614 | Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation |
| Q38349213 | Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? |
| Q57176290 | Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation |
| Q98163846 | Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib |
| Q52310616 | Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. |
| Q37522548 | Biology of chronic graft-vs-host disease: Immune mechanisms and progress in biomarker discovery. |
| Q90029171 | Biology-driven developments in the therapy of acute graft-versus-host disease |
| Q37638846 | CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. |
| Q39002164 | Chronic graft-versus-host disease: biological insights from preclinical and clinical studies |
| Q57281984 | Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes |
| Q47952891 | Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant |
| Q38569146 | Current Challenges in Stem Cell Transplantation in Myelofibrosis |
| Q39401817 | Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment |
| Q92535243 | Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies |
| Q90167003 | Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD |
| Q90751374 | Developing role of B cells in the pathogenesis and treatment of chronic GVHD |
| Q57194209 | Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10 |
| Q92072381 | Emerging Topical and Systemic JAK Inhibitors in Dermatology |
| Q59134954 | Essential role of IFN-γ in T cell-associated intestinal inflammation |
| Q42557675 | Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo. |
| Q89647000 | FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease |
| Q39281002 | Get a grip on immune cells by inhibiting JAKs |
| Q96302550 | Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation |
| Q38570383 | Immunological Consequences of JAK Inhibition: Friend or Foe? |
| Q37114440 | Immunological basis for treatment of graft versus host disease after liver transplant |
| Q26752528 | Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation |
| Q33774610 | Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target |
| Q42660823 | JAK inhibitors and myelofibrosis, Einstein and ruxolitinib |
| Q48109284 | JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. |
| Q38839108 | JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer |
| Q27003058 | JAK2 activation by growth hormone and other cytokines |
| Q97646648 | Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019 |
| Q59806674 | Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease |
| Q89767651 | Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults |
| Q91587430 | Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib |
| Q90249953 | Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis |
| Q39002166 | Mechanistic approaches for the prevention and treatment of chronic GVHD. |
| Q51013857 | MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. |
| Q39027845 | Myelofibrosis: to transplant or not to transplant? |
| Q41949169 | NK cell modulation by JAK inhibition |
| Q49791828 | Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset |
| Q49238507 | New and emerging therapies for acute and chronic graft versus host disease |
| Q38221028 | Next generation treatment of acute graft-versus-host disease |
| Q39023963 | Novel targets in the treatment of chronic graft-versus-host disease |
| Q34301568 | Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect |
| Q37035815 | Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? |
| Q52651223 | Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib. |
| Q62818939 | Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes |
| Q40086569 | Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation |
| Q26851417 | Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors |
| Q96431807 | Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients |
| Q92528596 | Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation |
| Q98771818 | Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol |
| Q64055485 | Ruxolitinib for Therapy of Graft-versus-Host Disease |
| Q90237307 | Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial |
| Q89777237 | Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis |
| Q59336540 | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) |
| Q36862931 | Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey |
| Q91174334 | Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study |
| Q42255208 | Ruxolitinib in steroid refractory graft-vs.-host disease: a case report |
| Q48251531 | Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. |
| Q93106885 | Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease |
| Q95648233 | Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level |
| Q51411675 | Ruxolitinib treatment for GvHD in patients with myelofibrosis. |
| Q92327065 | Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT |
| Q102141667 | Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease |
| Q33417217 | Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms |
| Q90479728 | Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions |
| Q47158588 | Serum and Extracellular Vesicle MicroRNAs miR-423, miR-199, and miR-93* As Biomarkers for Acute Graft-versus-Host Disease |
| Q38567540 | Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis |
| Q54254821 | Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function. |
| Q50062411 | TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model |
| Q52927960 | Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. |
| Q39337533 | Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors |
| Q48139357 | Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. |
| Q28076264 | The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease |
| Q55024258 | The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. |
| Q64257524 | The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease |
| Q53095310 | The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. |
| Q49384876 | The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. |
| Q28068647 | The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease |
| Q49222418 | Therapeutic effects of STAT3 inhibition by nifuroxazide on murine acute graft graft-vs.-host disease: Old drug, new use. |
| Q90601512 | Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease |
| Q26751959 | Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies |
| Q91522442 | Treatment and unmet needs in steroid-refractory acute graft-versus-host disease |
| Q36290517 | Treatment of Experimental Candida Sepsis with a Janus Kinase Inhibitor Controls Inflammation and Prolongs Survival |
| Q38742863 | Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation? |
| Q42737499 | Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. |
Search more.